Dusigitumab

Dusigitumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IGF2
Clinical data
ATC code	none;
Identifiers
CAS Number	1204390-13-5;
IUPHAR/BPS	7749;
ChemSpider	none;
UNII	0Z70DT5PRX;
KEGG	D10352;
Chemical and physical data
Formula	C6372H9824N1700O2016S54
Molar mass	144233.81 g·mol−1

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.^[1]^[2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.^[3] Its development has been discontinued.^[2]

References

^ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
^ ^a ^b Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
^ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.

[1] "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.

[Osher_2019-2] Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.

[3] "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]